Trial Library has raised US$10m Series A to expand its platform connecting patients in community clinics with trial access.

The AI platform links patients to studies through local clinics and operates across more than 320 clinics and 1,500 providers in the US. Total funding now stands at US$15m.

The platform uses AI-enabled provider activation, compliant eligible patient identification and longitudinal navigation, meaning ongoing support through screening, enrolment and follow-up. Trial Library is expanding partnerships with payers including self-insured plans and health plans.

“As a physician-scientist, I witnessed, first-hand, the significant impact clinical trials have on improved healthcare outcomes,” said Dr Hala Borno, chief executive and founder of Trial Library. “At Trial Library, we’re building the connective tissue that links care delivery and clinical research. This latest funding will enable us to advance our model where access to innovation is the standard, not the exception.”

Since launching in 2022, work with The Oncology Institute generated 642 patient referrals in one year, while American Oncology Network identified tens of eligible patients for solid tumour trials in its first quarter.

Trial Library has expanded its collaboration with Johnson & Johnson Innovative Medicine to support oncology clinical development and medical affairs programmes. In 2025, it announced a collaboration with Texas Oncology to streamline access through personalised patient navigation.

The company reports that 69 per cent of referrals are non-white, 29 per cent are on Medicaid and 44 per cent need transport support, addressing gaps in participation while reducing administrative burden on providers.

The round was co-led by SemperVirens Venture Capital and Next Ventures, with participation from Sanofi Ventures, Lux Capital, Civilization Ventures, How Women Invest, Overwater Ventures and others.

“Trial Library is the first technology company to unlock the payer market to effectively broaden the pool of patients who are considered for clinical trials,” said Allison Baum Gates, general partner at SemperVirens Venture Capital. “We’re excited to back a platform that aligns incentives and unites patients, providers, payers, and life-science partners around shared cost-savings and patient outcomes.”

Cris De Luca, partner at Sanofi Ventures, said: “Trial Library is a uniquely end-to-end platform, building the AI infrastructure that is accelerating access to the next generation of precision medicine.”

“Trial Library’s approach aligns with the growing shift toward decentralised, community-based research,” said Lance Armstrong, managing partner at Next Ventures. “They’re proving that AI and human navigation together can bring precision medicine to every corner of healthcare.”